A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT05592990
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇬🇧Novartis Investigative Site, Glasgow, United Kingdom
🇺🇸Tucson Orthopedic Institute, Tucson, Arizona, United States
Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)
- Conditions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05583604
A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT05576792
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2101
- Registration Number
- NCT05576779
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT05569174
- Locations
- 🇩🇪
Novartis Investigative Site, Schoenebeck, Germany
Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT05569187
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, SP, Brazil
Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 307
- Registration Number
- NCT05566756
- Locations
- 🇩🇪
Novartis Investigative Site, Unterhaching, Germany
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 191
- Registration Number
- NCT05562934
- Locations
- 🇺🇸
Jacksonville Center for Clinical Research Main Centre, Jacksonville, Florida, United States
🇺🇸Pinnacle Research Group Llc ., Anniston, Alabama, United States
🇺🇸Parkway Medical Center Research Department, Birmingham, Alabama, United States
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT05562466
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT05552469
- Locations
- 🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Mayo Clinic - Rochester, Rochester, Minnesota, United States